Novartis Raises Sales Forecast for Three Major Drugs to $18 Billion, Expected Annual Growth Rate of 5% by 2031
Novartis has raised the peak sales forecast for three major drugs from $14 billion to $18 billion. The company predicts that the annual sales growth will reach 5% by 2031, slightly down from the previous guidance of 5%-6% until 2030, with a change in the statistical period. Novartis aims to offset the financial impact of patent expirations on older drugs with strong market demand. The combined peak sales of Kesimpta, a treatment for multiple sclerosis, the leukemia drug Scemblix, and the cholesterol-lowering drug Leqvio are expected to reach $18 billion. Novartis's stock fell 2.4% in early trading in Switzerland. Investors are concerned about whether these three drugs can achieve rapid growth amid competition from lower-priced alternatives, compensating for lost revenue. CEO Vas Narasimhan stated that the outlook adjustment considers the expected competition in the U.S. generic drug market for the breast cancer treatment drug Kisqali, which is anticipated to begin in the second half of 2031.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027

Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care

Real-Life Theranos: New Blood Testing Startup Claims to Predict Health Risks

Sellas Life Sciences Cancer Vaccine Extends Patient Survival in Blood Cancer Clinical Trial

Moderna's Cancer Vaccine Shows Promise, Stock Valuation Raises Concerns

NVIDIA Launches Nemotron for Science to Accelerate Scientific Discoveries with Intelligent Agents

FDA Rejects Approval of Kangfang Biotech's Cancer Drug Ivonescimab

Former Employee Sues Ethereum Foundation, Claims Retaliatory Dismissal After Protesting 'Seppuku' Clause

BRT.Fit Founder Calls for Incorporating Exercise Habits into Cancer Prevention

Nixo sues Ethereum Foundation, Vitalik Buterin over 'suicide pledge' claim

U.S. Senate Rejects Long-Term Regulation Legislation for the Cryptocurrency Industry

Proteomic clocks link accelerated aging to higher risk of death and disease

Aging is not linear: cells go through coordinated stages of deterioration

Trump and Islamophobia: The Chorus That No Longer Mobilizes Votes

Jennifer Tilly Earns Up to $10 Million a Year from The Simpsons Without Ever Participating: Her Story

UK to ban crypto exchanges from making markets on their own platforms as Bitcoin rules change

Here Are the 4 Investing Rules I'm Never Breaking, No Matter How Scary the Stock Market Gets

Mr&强 Discusses Highlights of the ORIPA Project

Gold and silver lose $15 trillion, Bitcoin holds up better

Why Bitcoin’s quantum security upgrade may take years

The Industry Is Not Bad, But the $350 Billion Lost by ETH and SOL Is the Root Cause of Industry Pessimism

Prediction: These Will Be AMD’s and Nvidia’s Stock Prices by 2028

Crypto: Netflix Series on FTX Sparks Reactions from CZ and Vitalik Buterin

Solana upgrades to mainnet 1.0 as Foundation takes majority CoinGecko stake

IOSCO Warns of 'Quantum Delay' and Assesses Readiness for Quantum Threat

Deribit outage hit Bitcoin hedgers on Coinbase

Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?

J.P. Morgan Says Tesla's Robotaxi Fleet Could Match Waymo's Miles by Late 2027 With 18,000 Cars. The Number That Matters Is How Much Each Car Earns.

What's Going on with The Trade Desk Stock? 3 Reasons Investors Are Losing Confidence.







